Artificial intelligence is no longer a research-phase concept in biopharmaceutical manufacturing — it is an operational reality. In 2026, regulatory bodies in the United States, European Union, and South Korea are accepting AI-generated process characterization data as primary evidence in CMC submissions, marking a pivotal shift in how upstream biological processes are designed,...
Italiano 
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Russian
Romaian
Portuguese (Brazil)
Tiếng Việt